CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
atorvastatin calcium +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01220973
NCT01220973Phase 2Completed
CompareCT.gov

Phase II Trial of Atorvastatin and Celecoxib in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer.

Rutgers, The State University of New Jersey·interventional·Posted Oct 14, 2010·Updated Jun 8, 2018

In Brief

A Phase 2 clinical trial evaluating atorvastatin calcium, celecoxib, and 1 other intervention for Prostate Cancer. Completed, enrolled 27 participants across 4 sites.

Detailed Summary

RATIONALE: Atorvastatin calcium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atorvastatin calcium together with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving atorvastatin calcium together with celecoxib works in treating patients with rising PSA levels after local therapy for prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsRutgers Cancer Institute of New Jersey, National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 14, 2010
Enrollment StartFeb 1, 2009
Primary CompletionNov 18, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 15.7 years ago

Interventions

atorvastatin calciumdrug

celecoxibdrug

laboratory biomarker analysisother